tradingkey.logo

Oncology Institute Inc

TOI
2.610USD
+0.160+6.53%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
254.66MValor de mercado
PerdaP/L TTM

Oncology Institute Inc

2.610
+0.160+6.53%

Mais detalhes de Oncology Institute Inc Empresa

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Informações de Oncology Institute Inc

Código da empresaTOI
Nome da EmpresaOncology Institute Inc
Data de listagemMar 13, 2020
CEOVirnich (Daniel)
Número de funcionários825
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 13
Endereço18000 Studebaker Rd
CidadeCERRITOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal90703
Telefone15627353226
Sitehttps://theoncologyinstitute.com/
Código da empresaTOI
Data de listagemMar 13, 2020
CEOVirnich (Daniel)

Executivos da empresa Oncology Institute Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+12675.00%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+91049.00%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.13K
-244.00%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+3594.00%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
+98037.00%
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+12675.00%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+91049.00%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.13K
-244.00%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+3594.00%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
+98037.00%
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Por EmpresaUSD
Nome
Receita
Proporção
Dispensary revenue
75.89M
55.57%
FFS revenue
39.62M
29.01%
Capitated revenue
20.57M
15.07%
Clinical research trials and other revenue
474.00K
0.35%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Dispensary revenue
75.89M
55.57%
FFS revenue
39.62M
29.01%
Capitated revenue
20.57M
15.07%
Clinical research trials and other revenue
474.00K
0.35%

Distribuição de ações

Atualizado em: qua, 4 de fev
Atualizado em: qua, 4 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
M33 Growth LLC
5.53%
Chernett (Jorey)
5.20%
The Vanguard Group, Inc.
4.83%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
Outro
76.85%
Investidores
Investidores
Proporção
M33 Growth LLC
5.53%
Chernett (Jorey)
5.20%
The Vanguard Group, Inc.
4.83%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
Outro
76.85%
Tipos de investidores
Investidores
Proporção
Investment Advisor
12.45%
Hedge Fund
11.07%
Investment Advisor/Hedge Fund
10.11%
Individual Investor
10.09%
Venture Capital
5.53%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
Outro
45.22%

Participação acionária institucional

Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
172
39.71M
40.37%
-15.56M
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
M33 Growth LLC
5.44M
5.53%
-3.08M
-36.13%
Nov 18, 2025
The Vanguard Group, Inc.
4.55M
4.62%
+264.36K
+6.18%
Sep 30, 2025
OncologyCare Partners LLC
4.11M
4.18%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.42%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
3.17%
+119.92K
+4.00%
Sep 30, 2025
CenterBook Partners LP
2.70M
2.75%
+1.99M
+277.80%
Sep 30, 2025
Balyasny Asset Management LP
2.52M
2.56%
--
--
Sep 30, 2025
Kanen Wealth Management, LLC
1.84M
1.87%
+1.84M
--
Sep 30, 2025
Wexford Capital LP
1.57M
1.6%
+452.39K
+40.44%
Sep 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
Proporção0.11%
iShares Micro-Cap ETF
Proporção0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.03%
Global X Russell 2000 ETF
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI